Th17-cytokine blockers as a new approach for treating inflammatory bowel disease

References

• Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007;117:514–21.
   PubMed Web of Science ®Google Scholar
• Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573–621.
   PubMed Web of Science ®Google Scholar
• Fais S, Capobianchi MR, Pallone F, Di Marco P, Boirivant M, Dianzani F, . Spontaneous release of interferon gamma by intestinal lamina propria lymphocytes in Crohn's disease. Kinetics of in vitro response to interferon gamma inducers. Gut. 1991;32:403–7.
   PubMed Web of Science ®Google Scholar
• Isaacs KL, Sartor RB, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology. 1992;103:1587–95.
   PubMed Web of Science ®Google Scholar
• Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F, . Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology. 1997;112:1169–78.
   PubMed Web of Science ®Google Scholar
• Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, . Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157: 1261–70.
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, . A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029–35.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132:52–65.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, . A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005;129:807–18.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–57.
   PubMed Web of Science ®Google Scholar
• Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol. 2008;103:944–8.
   PubMed Web of Science ®Google Scholar
• Ma HL, Napierata L, Stedman N, Benoit S, Collins M, Nickerson-Nutter C, . Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum. 62:430–40.
   Google Scholar
• Quispel R, van der Worp HB, Pruissen M, Schipper ME, Oldenburg B. Fatal aseptic meningoencephalitis following infliximab treatment for inflammatory bowel disease. Gut. 2006;55:1056.
   Google Scholar
• Nunez Martinez O, Ripoll Noiseux C, Carneros Martin JA, Gonzalez Lara V, Gregorio Maranon HG. Reactivation tuberculosis in a patient with anti-TNF-alpha treatment. Am J Gastroenterol. 2001;96:1665–6.
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009;30:253–64.
   PubMed Web of Science ®Google Scholar
• Passarini B, Infusino SD, Barbieri E, Varotti E, Gionchetti P, Rizzello F, . Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy. Dermatology. 2007;215:295–300.
   PubMed Web of Science ®Google Scholar
• Neurath MF, Weigmann B, Finotto S, Glickman J, Nieuwenhuis E, Iijima H, . The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med. 2002;195:1129–43.
   PubMed Web of Science ®Google Scholar
• Parrello T, Monteleone G, Cucchiara S, Monteleone I, Sebkova L, Doldo P, . Up-regulation of the IL-12 receptor beta 2 chain in Crohn's disease. J Immunol. 2000; 165:7234–9.
   PubMed Web of Science ®Google Scholar
• Reinisch W, de Villiers W, Bene L, Simon L, Racz I, Katz S, . Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis. 2010; 16:233–42.
   PubMed Web of Science ®Google Scholar
• Hommes DW, Mikhajlova TL, Stoinov S, Stimac D, Vucelic B, Lonovics J, . Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut. 2006;55:1131–7.
   PubMed Web of Science ®Google Scholar
• Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008;28:454–67.
   PubMed Web of Science ®Google Scholar
• Seiderer J, Elben I, Diegelmann J, Glas J, Stallhofer J, Tillack C, . Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis. 2008;14:437–45.
   PubMed Web of Science ®Google Scholar
• Dambacher J, Beigel F, Zitzmann K, De Toni EN, Göke B, Diepolder HM, . The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut. 2009;58:1207–17.
   PubMed Web of Science ®Google Scholar
• Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, . IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol. 2006;290:G827–38.
   PubMed Web of Science ®Google Scholar
• Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, . Phenotypic and functional features of human Th17 cells. J Exp Med. 2007;204:1849–61.
   PubMed Web of Science ®Google Scholar
• Monteleone G, Monteleone I, Fina D, Vavassori P, Del Vecchio Blanco G, Caruso R, . Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology. 2005;128: 687–94.
   PubMed Web of Science ®Google Scholar
• Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, . Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature. 2007;448:480–3.
   PubMed Web of Science ®Google Scholar
• Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, . IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8:967–74.
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, . IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature. 2007;448:484–7.
   PubMed Web of Science ®Google Scholar
• Sarra M, Monteleone I, Stolfi C, Fantini MC, Sileri P, Sica G, . Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm Bowel Dis. 2010;16:1332–9.
   PubMed Web of Science ®Google Scholar
• Caruso R, Fina D, Peluso I, Stolfi C, Fantini MC, Gioia V, . A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology. 2007;132:166–75.
   PubMed Web of Science ®Google Scholar
• Kwon JH, Keates S, Bassani L, Mayer LF, Keates AC. Colonic epithelial cells are a major site of macrophage inflammatory protein 3alpha (MIP-3alpha) production in normal colon and inflammatory bowel disease. Gut. 2002;51:818–26.
   PubMed Web of Science ®Google Scholar
• Pelletier M, Maggi L, Micheletti A, Lazzeri E, Tamassia N, Costantini C, . Evidence for a cross-talk between human neutrophils and Th17 cells. Blood. 2010;115:335–43.
   PubMed Web of Science ®Google Scholar
• Monteleone G, Caruso R, Fina D, Peluso I, Gioia V, Stolfi C, . Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut. 2006;55:1774–80.
   PubMed Web of Science ®Google Scholar
• Liu Z, Yang L, Cui Y, Wang X, Guo C, Huang Z, . Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1133–44.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zheng M, Bindas J, Schwarzenberger P, Kolls JK. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis. 2006;12:382–8.
   PubMed Web of Science ®Google Scholar
• Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 2003;14:155–74.
   PubMed Web of Science ®Google Scholar
• Yang XO, Chang SH, Park H, Nurieva R, Shah B, Acero L, . Regulation of inflammatory responses by IL-17F. J Exp Med. 2008;205:1063–75.
   PubMed Web of Science ®Google Scholar
• Ito R, Kita M, Shin-Ya M, Kishida T, Urano A, Takada R, . Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice. Biochem Biophys Res Commun. 2008;377:12–16.
   PubMed Web of Science ®Google Scholar
• Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, . Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology. 2007;132:2359–70.
   PubMed Web of Science ®Google Scholar
• Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, . IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233–40.
   PubMed Web of Science ®Google Scholar
• Brombacher F, Kastelein RA, Alber G. Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol. 2003;24:207–12.
   PubMed Web of Science ®Google Scholar
• Tajima M, Wakita D, Noguchi D, Chamoto K, Yue Z, Fugo K, . IL-6-dependent spontaneous proliferation is required for the induction of colitogenic IL-17-producing CD8+ T cells. J Exp Med. 2008;205:1019–27.
   PubMed Web of Science ®Google Scholar
• Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, . A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med. 2009;15:1016–22.
   PubMed Web of Science ®Google Scholar
• O'Connor W Jr, Kamanaka M, Booth CJ, Town T, Nakae S, Iwakura Y, . A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol. 2009;10:603–9.
   PubMed Web of Science ®Google Scholar
• Leppkes M, Becker C, Ivanov II, Hirth S, Wirtz S, Neufert C, . RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology. 2009;136:257–67.
   PubMed Web of Science ®Google Scholar
• Noguchi D, Wakita D, Tajima M, Ashino S, Iwakura Y, Zhang Y, . Blocking of IL-6 signaling pathway prevents CD4+ T cell-mediated colitis in a T(h)17-independent manner. Int Immunol. 2007;19:1431–40.
   PubMed Web of Science ®Google Scholar
• McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T, . TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol. 2007;8:1390–7.
   PubMed Web of Science ®Google Scholar
• Fina D, Sarra M, Fantini MC, Rizzo A, Caruso R, Caprioli F, . Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology. 2008;134: 1038–48.
   PubMed Web of Science ®Google Scholar
• Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, . IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006;116:1310–6.
   PubMed Web of Science ®Google Scholar
• Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, . Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med. 2006;203: 2473–83.
   PubMed Web of Science ®Google Scholar
• Kullberg MC, Jankovic D, Feng CG, Hue S, Gorelick PL, McKenzie BS, . IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J Exp Med. 2006;203:2485–94.
   PubMed Web of Science ®Google Scholar
• Izcue A, Hue S, Buonocore S, Arancibia-Carcamo CV, Ahern PP, Iwakura Y, . Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity. 2008;28:559–70.
   PubMed Web of Science ®Google Scholar
• Becker C, Dornhoff H, Neufert C, Fantini MC, Wirtz S, Huebner S, . Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J Immunol. 2006;177:2760–4.
   PubMed Web of Science ®Google Scholar
• Kamada N, Hisamatsu T, Okamoto S, Chinen H, Kobayashi T, Sato T, . Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest. 2008;118:2269–80.
   PubMed Web of Science ®Google Scholar
• Kamada N, Hisamatsu T, Honda H, Kobayashi T, Chinen H, Takayama T, . TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease. Inflamm Bowel Dis. 2010;16:568–75.
   PubMed Web of Science ®Google Scholar
• Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, . Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med. 2004;351:2069–79.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, . A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008;135:1130–41.
   PubMed Web of Science ®Google Scholar
• Fuss IJ, Becker C, Yang Z, Groden C, Hornung RL, Heller F, . Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis. 2006;12:9–15.
   PubMed Web of Science ®Google Scholar
• Burakoff R, Barish CF, Riff D, Pruitt R, Chey WY, Farraye FA, . A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis. 2006;12: 558–65.
   PubMed Web of Science ®Google Scholar
• Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, . Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 184:5298–307.
   Google Scholar
• Nowell MA, Williams AS, Carty SA, Scheller J, Hayes AJ, Jones GW, . Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol. 2009;182:613–22.
   PubMed Web of Science ®Google Scholar
• Murase A, Okumura T, Sakakibara A, Tonai-Kachi H, Nakao K, Takada J. Effect of prostanoid EP4 receptor antagonist, CJ-042,794, in rat models of pain and inflammation. Eur J Pharmacol. 2008;580:116–21.
   Google Scholar
• Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Bhan AK, . IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest. 2008;118:534–44.
   PubMed Web of Science ®Google Scholar
• Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, Fisher SA, . Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet. 2007;39:830–2.
   PubMed Web of Science ®Google Scholar
• Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, . 16.A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314:1461–3.
   PubMed Web of Science ®Google Scholar
• Festen EA, Goyette P, Scott R, Annese V, Zhernakova A, Lian J, . Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut. 2009;58: 799–804.
   PubMedGoogle Scholar
• Schmechel S, Konrad A, Diegelmann J, Glas J, Wetzke M, Paschos E, . Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status. Inflamm Bowel Dis. 2008;14:204–12.
   PubMed Web of Science ®Google Scholar
• Jones JL, Phuah CL, Cox AL, Thompson SA, Ban M, Shawcross J, . IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Inves. 2009;119:2052–61.
   PubMed Web of Science ®Google Scholar